Park Chan Su, Park Byung Kyu, Han Joung-Ho, Lee Kyong Joo, Son Kang Ju
Division of Gastroenterology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang 10444, Republic of Korea.
Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju 28644, Republic of Korea.
Cancers (Basel). 2024 Sep 16;16(18):3173. doi: 10.3390/cancers16183173.
BACKGROUND/OBJECTIVES: This nationwide population-based study investigated the overall survival (OS) of patients with metastatic pancreatic cancer (mPC) receiving first-line chemotherapy.
Data from the National Health Insurance Service linked to the Korea Central Cancer Registry were used. Patients with mPC receiving first-line chemotherapy (2012-2019) were included and followed up until 2020. The gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX groups were matched according to age, sex, and comorbidities.
In total, 8652 patients with mPC were treated with chemotherapy. GnP and FOLFIRINOX have been administered since 2016 and 2017, respectively. The median OS increased annually from 6 months in 2012-2013 to 10 months in 2018-2019. The median OSs in the GnP and FOLFIRINOX groups were significantly longer than those in patients receiving gemcitabine ± erlotinib. A total of 1134 patients from both the GnP and FOLFIRINOX groups were selected using propensity score matching. Before matching, the median OS was longer in the FOLFIRINOX group than in the GnP group ( = 0.0029). After matching, however, there was no significant difference in the median OS between the two groups (11 vs. 11 months, respectively, = 0.2438).
Patients with mPC receiving chemotherapy have shown improved OS since the introduction of GnP and FOLFIRINOX. After matching, OS did not differ between the GnP and FOLFIRINOX groups.
背景/目的：这项基于全国人群的研究调查了接受一线化疗的转移性胰腺癌（mPC）患者的总生存期（OS）。
使用与韩国中央癌症登记处相关联的国民健康保险服务数据。纳入接受一线化疗（2012 - 2019年）的mPC患者，并随访至2020年。吉西他滨联合白蛋白结合型紫杉醇（GnP）组和FOLFIRINOX组根据年龄、性别和合并症进行匹配。
共有8652例mPC患者接受了化疗。GnP和FOLFIRINOX分别自2016年和2017年开始应用。中位总生存期从2012 - 2013年的6个月逐年增加至2018 - 2019年的10个月。GnP组和FOLFIRINOX组的中位总生存期显著长于接受吉西他滨±厄洛替尼治疗的患者。使用倾向评分匹配从GnP组和FOLFIRINOX组中总共选取了1134例患者。匹配前，FOLFIRINOX组的中位总生存期长于GnP组（P = 0.0029）。然而，匹配后，两组的中位总生存期无显著差异（分别为11个月和11个月，P = 0.2438）。
自引入GnP和FOLFIRINOX以来，接受化疗的mPC患者的总生存期有所改善。匹配后，GnP组和FOLFIRINOX组的总生存期无差异。
